Loading clinical trials...
Loading clinical trials...
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Pilot and Dose-Ranging Study of GDC-0853 in Patients With Refractory Chronic Spontaneous Urticaria (CSU).
Conditions
Interventions
GDC-0853
Placebo
Locations
27
United States
Clinical Research Center of Alabama, LLC
Birmingham, Alabama, United States
Allergy & Asthma Immunology Associates
Scottsdale, Arizona, United States
Kern Allergy Med Clinic, Inc.
Bakersfield, California, United States
Southern California Research Center
Mission Viejo, California, United States
Allergy & Asthma Consultants
Redwood City, California, United States
Integrated Research Group Inc
Riverside, California, United States
Start Date
May 26, 2017
Primary Completion Date
September 27, 2019
Completion Date
October 25, 2019
Last Updated
September 29, 2020
NCT07358364
NCT06544018
NCT07266402
NCT06931405
NCT07359430
NCT03004326
Lead Sponsor
Genentech, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions